Australian Sponsor Qualification and Statutory Duties

1. Key takeaways

The obligations of an Australian sponsor rest on two parallel tracks. The first track is the set of “automatic conditions” in section 41FN of the Therapeutic Goods Act 1989, which take effect the moment the device is included in the ARTG. The second track is formed by the reporting, record-keeping and annual declaration provisions of the Therapeutic Goods (Medical Devices) Regulations 2002. On top of both tracks, TGA’s official position requires the sponsor to be a recognised legal entity within Australia.

• Sponsor obligations are automatic: inspection cooperation, sample supply, evidence availability and reporting duties begin at inclusion, not upon notification.
• Adverse event reporting follows three time tiers of 48 hours, 10 days and 30 days, counted from the date of awareness.
• Distribution records must extend to every individual device, with 10-year and 5-year retention tiers.
• Annual reports for Class III devices, Class IIb implantable devices and Class 4 IVDs fall due before 1 October each year.
• Labelling failures carry a penalty of 10 penalty units.

Taken together, the two tracks mean that an Australian sponsor is not merely a name on the register. The sponsor is the compliance hub through which inspection cooperation, sample supply, evidence management, adverse event reporting and annual declarations all flow, and each of those flows carries its own statutory clock.

2. Legal basis

Each obligation below is mapped to its source provision. The citations are drawn from the Therapeutic Goods Act 1989, the Therapeutic Goods (Medical Devices) Regulations 2002 and TGA’s published guidance on the sponsor role.

1. Therapeutic Goods Act 1989 (Act No. 21, 1990, compilation C2004A03952): the definition of sponsor in section 3(1) covers a person who exports or arranges the export of, imports or arranges the import of, or manufactures or arranges the manufacture of the device in Australia, but excludes a person who does any of these things on behalf of another person who resides in Australia or carries on business in Australia. The definition of manufacturer appears in section 41BG(1)–(4).
2. Automatic conditions (section 41FN): 41FN(1) requires the sponsor to accept entry by authorised persons into premises for inspection and sampling; 41FN(2) requires supply of samples on request, with a notice period of at least 10 working days; 41FN(3) requires evidence of conformity to be held at all times, or a written agreement with the manufacturer ensuring it can be obtained within 20 working days of a request; 41FN(5) concerns advertising material.
3. Adverse event reporting: Therapeutic Goods (Medical Devices) Regulations 2002 (F2002B00237, compilation F2026C00883) regulation 5.7(1) — events constituting a serious threat to public health are reported within 48 hours; events leading to death or serious deterioration of health within 10 days; events that could lead to death or serious deterioration within 30 days. Regulation 5.8A requires a written investigation report, covering similar events over the past 3 years, within 120 days of the report.
4. Record-keeping: regulation 5.10 — complaint and problem records plus distribution records for every individual device; Class III, Class IIb implantable and Class 4 IVD records are kept for 10 years, all other classes for 5 years.
5. Annual reporting: regulation 5.11 — Class III devices, Class IIb implantable devices and Class 4 IVDs are reported annually before 1 October.
6. Labelling: regulation 10.2 — the sponsor’s name and address must accompany the device (penalty: 10 penalty units).
7. Penalties: section 41MP (criminal, 12 months imprisonment or 1,000 penalty units) and section 41MPA (civil penalties, 3,000 penalty units for an individual and 30,000 penalty units for a body corporate). Section 41KA allows the Secretary to impose requirements relating to public warning and recall.
8. TGA official position: the sponsor must be a recognised legal entity within Australia (TGA, Medical device inclusion process, 23 November 2023).

3. Expert insights

Insight 1: the exclusion clause in section 3(1) is often overlooked. Where an overseas manufacturer imports, or arranges the import of, a device on behalf of an Australian party, that manufacturer does not qualify as a sponsor. This single clause determines who the responsible entity actually is, and therefore who the supporting agreements should be signed with.

Insight 2: automatic conditions take effect without any notice. From the moment an ARTG number is issued, the duties of inspection cooperation, sample delivery, evidence availability and reporting all operate simultaneously. During any period in which the company is “waiting for TGA to say something”, the obligations are already running.

Insight 3: reporting clocks start at awareness, not at the event. The three time tiers in regulation 5.7 are counted from the day the sponsor becomes aware of the incident. This demands an internal escalation mechanism that is triggered by awareness itself, rather than a monthly summary process. In practical terms this means that every complaint intake channel — customer service, distributor feedback, literature alerts and social media — must route into a single triage point that can classify an event within hours and start the statutory clock deliberately rather than accidentally.

4. Practical recommendations

• Build a sponsor obligations register that maps every paragraph of section 41FN and regulations 5.7, 5.8A, 5.10, 5.11 and 10.2 to a concrete action and a named owner.
• Sign a written agreement with the manufacturer that embeds the 20 working days evidence-obligation duty and states the consequences of breach.
• Establish an adverse event escalation flow that is triggered on awareness, with response levels configured against the 48-hour, 10-day and 30-day tiers.
• Complete the annual report before 1 October each year, and reconcile it against the status of annual charge payments (see article 38).

5. Verification checklist

• □ Sponsor identity has been determined and no section 3(1) exclusion applies
• □ Each paragraph of section 41FN has been mapped to an executable action
• □ The manufacturer agreement contains the 20 working days evidence obligation
• □ Response levels are configured for the 48-hour, 10-day and 30-day reporting tiers
• □ Record retention periods are layered at 10 years and 5 years
• □ Annual report and annual charge milestones are in the compliance calendar

Regulatory information verified as of 29 October 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team coordinates Australian sponsor arrangements, ARTG annual charges, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com